GWM
ABBV icon

Geneos Wealth Management’s AbbVie ABBV Stock Holding History

Geneos Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.04M Sell
36,958
-239
-0.6% -$53K 0.19% 124
2025
Q4 		$8.5M Buy
37,197
+547
+1% +$125K 0.21% 122
2025
Q3 		$8.49M Sell
36,650
-2,649
-7% -$539K 0.22% 121
2025
Q2 		$7.29M Sell
39,299
-41,832
-52% -$7.77M 0.18% 142
2025
Q1 		$17M Buy
81,131
+49,222
+154% +$9.57M 0.24% 100
2024
Q4 		$5.67M Sell
31,909
-306
-0.9% -$56.3K 0.2% 114
2024
Q3 		$6.36M Buy
32,215
+2,784
+9% +$520K 0.24% 98
2024
Q2 		$5.05M Sell
29,431
-285
-1% -$47.2K 0.22% 102
2024
Q1 		$5.41M Sell
29,716
-843
-3% -$145K 0.25% 95
2023
Q4 		$4.74M Sell
30,559
-4,369
-13% -$637K 0.23% 109
2023
Q3 		$5.21M Sell
34,928
-1,565
-4% -$230K 0.27% 97
2023
Q2 		$4.92M Buy
36,493
+2,486
+7% +$365K 0.26% 101
2023
Q1 		$5.42M Sell
34,007
-4,612
-12% -$705K 0.33% 70
2022
Q4 		$6.24M Sell
38,619
-2,750
-7% -$422K 0.38% 59
2022
Q3 		$5.55M Sell
41,369
-16,537
-29% -$2.37M 0.38% 52
2022
Q2 		$8.9M Sell
57,906
-548
-0.9% -$83.7K 0.44% 44
2022
Q1 		$9.47M Sell
58,454
-4,222
-7% -$613K 0.41% 45
2021
Q4 		$8.49M Sell
62,676
-9,200
-13% -$1.09M 0.32% 57
2021
Q3 		$7.88M Buy
71,876
+644
+0.9% +$73.6K 0.3% 63
2021
Q2 		$8.2M Sell
71,232
-12,192
-15% -$1.37M 0.32% 64
2021
Q1 		$9.3M Buy
83,424
+1,613
+2% +$173K 0.26% 89
2020
Q4 		$7.65M Buy
81,811
+25,643
+46% +$2.46M 0.31% 68
2020
Q3 		$4.84M Sell
56,168
-4,340
-7% -$409K 0.25% 91
2020
Q2 		$5.82M Buy
60,508
+4,440
+8% +$391K 0.32% 74
2020
Q1 		$4.07M Buy
56,068
+4,373
+8% +$372K 0.27% 81
2019
Q4 		$4.61M Buy
51,695
+747
+1% +$62K 0.25% 112
2019
Q3 		$3.81M Buy
50,948
+169
+0.3% +$11.6K 0.23% 112
2019
Q2 		$3.69M Buy
50,779
+2,314
+5% +$182K 0.23% 113
2019
Q1 		$3.9M Sell
48,465
-432
-0.9% -$35.3K 0.26% 107
2018
Q4 		$4.46M Buy
48,897
+1,165
+2% +$102K 0.33% 76
2018
Q3 		$4.51M Buy
47,732
+11,844
+33% +$1.12M 0.3% 90
2018
Q2 		$3.33M Sell
35,888
-4,071
-10% -$398K 0.26% 106
2018
Q1 		$3.78M Sell
39,959
-134
-0.3% -$14.7K 0.33% 81
2017
Q4 		$3.88M Sell
40,093
-1,545
-4% -$146K 0.35% 83
2017
Q3 		$3.7M Sell
41,638
-4,295
-9% -$327K 0.37% 75
2017
Q2 		$3.33M Sell
45,933
-1,163
-2% -$78.2K 0.34% 80
2017
Q1 		$3.07M Buy
47,096
+720
+2% +$45.3K 0.32% 85
2016
Q4 		$2.9M Sell
46,376
-5,607
-11% -$342K 0.38% 75
2016
Q3 		$3.28M Buy
51,983
+7,152
+16% +$463K 0.44% 54
2016
Q2 		$2.81M Sell
44,831
-1,178
-3% -$71.8K 0.41% 58
2016
Q1 		$2.64M Buy
+46,009
New +$2.56M 0.4% 55

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geneos Wealth Management's ABBV Position: Q1 2026 in Review

Geneos Wealth Management reduced its AbbVie (ABBV) stake by 0.64% in Q1 2026, selling an estimated $53K and leaving 36,958 shares worth $8.04M. The position accounts for 0.19% of the portfolio, ranked #124.

Geneos Wealth Management first reported a position in ABBV in Q1 2016 and has held it in 41 quarters since. The position peaked at $17M in Q1 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Geneos Wealth Management held 36,958 shares of AbbVie worth $8.04M as of Q1 2026.
  • Geneos Wealth Management sold 239 AbbVie shares in Q1 2026, an estimated $53K.
  • AbbVie made up 0.19% of Geneos Wealth Management's portfolio in Q1 2026, its #124 holding.
  • Geneos Wealth Management first reported a position in AbbVie in Q1 2016 and has held it in 41 quarters since.
  • Geneos Wealth Management's AbbVie position peaked at $17M in Q1 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.